Pulmonary rehabilitation 2007: From bench to practice and back

Decramer1, Marc
October 2008
Clinical & Investigative Medicine;Oct2008, Vol. 31 Issue 5, pE312
Academic Journal
COPD is a disease that is not confined to the airways and the lungs, but also produces systemic consequences. Muscle weakness is one of these. It is produced by a multitude of factors including deconditioning, systemic inflammation, oxidative stress, nutritional imbalance, reduced anabolic status, systemic corticosteroids, hypoxemia, hypercapnia, electrolyte disturbances, cardiac failure. The most important factors appear to be inactivity and systemic inflammation. Inactivity was shown to be present in patients with COPD from early in the course of the disease on. Systemic inflammation was shown to be predominantly present during COPD exacerbations. IL-6 has the propensity to reduce muscle function in experimental animals. At present there is no evidence of local production of cytokines in the muscle in patients with COPD. Muscle weakness is also important in the clinical course of the disease as it is associated with exercise intolerance, reduced quality of life, enhanced utilization of health care resources and reduced survival. Rehabilitation is the best treatment for muscle weakness and deconditioning in patients with COPD. Indeed, it is the intervention with the largest effect on health status and exercise capacity in these patients. Several factors that may enhance the effects of rehabilitation have been studied. These include: growth hormone/ IGF-I, anabolic steroids, clenbuterol, creatine, anti-cytokine treatment, erythropoietin, oxygen, non-invasive mechanical ventilation and electrical stimulation. Recently, the potential of protease-inhibitors in reversing deconditioning-induced muscle dysfunction was demonstrated. Adjuncts are potentially particularly useful in patients who do not respond to a rehabilitation programme. Analysis of large d-bases demonstrated that about one third of the patients does not respond to rehabilitation. A follow-up study suggests that decline in exercise capacity after a rehabilitation programme is particularly present in these patients and not in the patients with a clear initial response. A better understanding of the factors controlling the response to rehabilitation, may lead to significant advances in this field.


Related Articles

  • Oxidant-induced corticosteroid unresponsiveness in human bronchial epithelial cells. Heijink, Irene; van Oosterhout, Antoon; Kliphuis, Nathalie; Jonker, Marnix; Hoffmann, Roland; Telenga, Eef; Klooster, Karin; Slebos, Dirk-Jan; Hacken, Nick ten; Postma, Dirkje; van den Berge, Maarten // Thorax;Jan2014, Vol. 69 Issue 1, p5 

    Background We hypothesised that increased oxidative stress, as present in the airways of asthma and chronic obstructive pulmonary disease (COPD) patients, induces epithelial damage and reduces epithelial responsiveness to suppressive effects of corticosteroids on proinflammatory cytokine...

  • Asthma: clinical assessment.  // Thorax;Dec2004 Supplement, Vol. 59, p50 

    The article presents some papers related to clinical assessment of asthma. There is currently great interest in developing non-invasive measures of airway inflammation in asthma. Proposed markers of airway inflammation and or oxidative stress in asthma include the exhaled gases, nitric oxide...

  • COPD exacerbations · 5: Management. Rodríguez-Roisin, R. // Thorax;Jun2006, Vol. 61 Issue 6, p535 

    The article presents a review of the most crucial evidence based therapeutic options for the management of exacerbations of Chronic Obstructive Pulmonary Disease (COPD). Exacerbations of COPD have the characteristics of enhanced airway inflammation and oedema and systemic inflammation, leading...

  • The Vasculature as a Target in the Treatment of Pulmonary Emphysema. Golpon, H. A.; Voelkel, N. F. // Current Drug Targets;Jun2006, Vol. 7 Issue 6, p737 

    Pulmonary emphysema, a major component of chronic obstructive pulmonary diseases, is a highly prevalent progressive tissue-destructive disease, with no effective treatments. The interplay between inflammation, matrix proteolysis, oxidative stress and apoptosis might account for the irreversible...

  • The genetics of chronic obstructive pulmonary disease. Wood, Alice M.; Stockley, Robert A. // Respiratory Research;2006, Vol. 7, p130 

    Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease caused by the interaction of genetic susceptibility and environmental influences. There is increasing evidence that genes link to disease pathogenesis and heterogeneity by causing variation in protease anti-protease systems,...

  • Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease. Bonay, M.; Bancal, C.; Crestani, B.; Bonay, Marcel; Bancal, Catherine; Crestani, Bruno // Drug Safety;2002, Vol. 25 Issue 1, p57 

    Inhaled corticosteroids have a proven benefit in the management of asthma, but until recently, their efficacy in non-asthmatic, smoking-related chronic obstructive pulmonary disease (COPD) was not evidence-based. Airway inflammation in COPD differs from inflammation in asthma. Some studies have...

  • Inhaled corticosteroids and COPD exacerbations. Kuritzky, Louis // Internal Medicine Alert;3/29/2010, Vol. 32 Issue 6, p48 

    The article reports on the effectiveness of inhaled corticosteroids (ICS) in treating acute exacerbations of chronic obstructive pulmonary disease (AC-COPD).

  • High-dose steroids cut COPD deaths. Polak, Monika // GP: General Practitioner;2/3/2003, p17 

    Reports on a study published in the 'European Respiratory Journal' stating that treating patients with medium and high dose of inhaled corticosteroids after discharge from hospital from chronic obstructive pulmonary disease (COPD) have a lower risk of deaths. Doses of steroids for patients with...

  • Discontinuing Inhaled Steroids in COPD Patients. Carter, Chuck // American Family Physician;4/15/2003, Vol. 67 Issue 8, p1803 

    Discusses the study 'Effect of Discontinuation of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease,' by P. Van der Valk et al., from the November 15, 2002 issue of the 'American Journal of Respiratory and Critical Care Medicine.'


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics